BOSTON - Eisai and Biogen presented five-year Clarity AD long-term extension results for Alzheimer's therapy lecanemab (Leqembi) on Nov. 16 at the CTAD 2026 conference in Boston. Continuous treatment slowed disease progression over five years with declining side-effect rates.
Risk of Dementia Progression Cut 49%
Across five years of continuous therapy, lecanemab cut the relative risk of progressing to the next disease stage by 36% and to moderate or severe dementia by 49% versus the ADNI natural-history cohort. Of the 1,795 core Phase 3 patients, 95% entered the extension and 351 completed five full years of treatment, showing 2.05 points less decline on the CDR-SB cognitive-functional scale than ADNI.
Low-Tau Subgroup Posts Strong Gains
Brain Swelling Rates Drop After Year One
Incidence of ARIA-E brain swelling fell steadily after the first year of infusions. Rates dropped from 13.5% in year one to 3.6% in year two, then stayed at 1.1%, 1.3%, and 0.6% in years three through five.


